Dheeraj Nagore

Dheeraj Nagore

Auto-generated profile, based on publicly available information

Dheeraj Nagore

Director, Mprex Healthcare Pvt., Ltd., Pune, Maharashtra, India

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Pharmacologia
Verified
Journal Article
Closed access
DNDheeraj H. Nagore
Dheeraj H. Nagore
HBHanumant U. Bhusnar
Hanumant U. Bhusnar
SNSanjay U. Nipanikar
Sanjay U. Nipanikar

22 December 2022 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
SPShridhar Pandya
Shridhar Pandya
CSChetan Savaliya
Chetan Savaliya
KTKamlesh Thummar
Kamlesh Thummar
AGAmol Gothwad
Amol Gothwad
TPTanuja Panchabhai
Tanuja Panchabhai
DNDheeraj Nagore
Dheeraj Nagore

1 August 2018 in Indian Journal of Pharmaceutical Education and Research
Verified
Journal Article
Open access
PGPurnima J Ganjage
Purnima J Ganjage
ATAmit S Tapkir
Amit S Tapkir
SNSanjay U Nipanikar
Sanjay U Nipanikar
DNDheeraj Hanumansingh Nagore
Dheeraj Hanumansingh Nagore
PPPrachi K Pawar
Prachi K Pawar
MPMonali L Phophase
Monali L Phophase

1 January 2023 in AYU (An International Quarterly Journal of Research in Ayurveda)
Verified
Journal Article
Open access
CSChetan Savaliya
Chetan Savaliya
SPShridhar Pandya
Shridhar Pandya
KTKamalesh Thumar
Kamalesh Thumar
DNDheeraj Nagore
Dheeraj Nagore
Background: The constructive role of Ayurveda in managing COVID-19 has been widely discussed, with identified herbs showing immunomodulatory and anti-viral potential. However, clinical trials examining their safety and efficacy are limited. Aim: The aim of this study is to determine the efficacy of COROPROTECT kit, a proprietary Ayurvedic formulation, in COVID-19. Materials and method: Randomized, placebo-controlled trial with 312 mild to moderate hospitalized COVID-19 patients. Groups received COROPROTECT or placebo for 10 days alongside standard care. Results: The outcome measures included the number of days taken to reverse the reverse transcriptase-polymerase chain reaction (RT-PCR) status, reduction in symptoms and inflammatory markers. Fisher exact test was used to analyze the changes between categorical variables, whereas the comparative effect of therapy in both groups on inflammatory markers and safety biochemical parameters was analyzed using Student’s t test. A total of 300 patients completed the study without any adverse events. The COROPROTECT kit group exhibited a statistically significant higher percentage of patients testing negative on days 4, 7, and 10 compared to the placebo group. A within group analysis showed that trial group to significantly reduced the levels of C-reactive protein (P = 0.03), lactate dehydrogenase (P < 0.001), and interleukin-6 (P = 0.01). Subjects of the trial group experienced complete relief from cough (69.33%), breathlessness (65.33%), and fatigue (62.67%) within 4 days. In contrast, the placebo group had 20%–40% of participants with mild symptoms persisting until day 10. Conclusion: This study suggests potential future implications, indicating a faster RT-PCR negativity, reduced COVID-19 severity, and inflammatory markers, along with early symptomatic recovery. The COROPROTECT kit proved safe, facilitating an accelerated clinical recovery compared to conventional care.

1 January 2023 in Journal of Orthopedics & Rheumatology
Verified
Journal Article
Open access
PDF file
DNDheeraj Nagore
Dheeraj Nagore
SPShridhar Pandya
Shridhar Pandya
CSChetan Savaliya
Chetan Savaliya
AGAmol Gothwad
Amol Gothwad
TPTanuja Panchabhai
Tanuja Panchabhai
GGGayatri Ganu
Gayatri Ganu
Background: Osteoarthritis (OA) is the most common joint disease with a prevalence of 22% to 39% in India and being foremost causes of nonfatal burden. The use of conventional medication can be associated with insufficient clinical management, serious side effects. The present research validates using Joint Support Product (JSP) a standardized, specially designed herbal extract-based formula with phytonutrients which are useful in the management of symptoms as well as regeneration in OA. Method: Clinical trial was randomized placebo-controlled involving 150 patients with knee osteoarthritis included in two parallel groups equally. JSP and placebo were provided for 90 days. The celecoxib tablets up to 200 mg as rescue was allowed and recorded. The objectives of the study were to assess the effectiveness and safety of JSP in osteoarthritis by evaluating pain, stiffness, symptoms and antiinflammatory activity to improve quality of life. Results: Treatment of JSP in patients with osteoarthritis led to reduction in pain, stiffness and other related parameters to provide the symptomatic relief and thus improved quality of life. Treatment with JSP reduced the inflammatory markers by 50% suggestive potential joint restorative action. With JSP, most of the subjects showed reduced dependency on the analgesics as a rescue. There were no evident side effects of the JSP treatment. Conclusion: It can be concluded from the study that JSP is safer and effective option in the management of OA. With treatment with JSP, most of the subjects showed reduced dependency on the analgesics as a rescue in the treatment tenure.

30 December 2022 in Bulletin of the Karaganda University. "Chemistry" Series
Verified
Journal Article
Closed access
SGSejal Gandhi
Sejal Gandhi
AGA.R. Gawhane
A.R. Gawhane
SKS.D. Kapse
S.D. Kapse
DND. Nagore
D. Nagore
SCSohan Chitlange
Sohan Chitlange
Simple, sensitive high performance thin layer chromatography method for the estimation of gallic acid and quercetin in in-house polyherbal blend has been developed and validated. Methanolic solution of herbal blend comprising of Emblica officinalis, Camellia sinensis and Garcinia cambogia was used for analysis. The sepa-ration was performed on TLC aluminum plates precoated with silica gel G60 F254 and toluene: ethyl ace-tate: formic acid (5:1.5:1 v/v/v) at 254 nm scanning wavelength. The system gave well resolved peaks for gal-lic acid and quercetin at Rf 0.14 and Rf 0.29 respectively. The method validated as per ICH Q2R1 guidelines which shows regression co-efficient 0.9939 for gallic acid and 0.9988 for quercetin in range of 2–6 μg/ml. Recovery of gallic acid and quercetin was found in range of 98–102 % which confirms the accuracy of meth-od. Precision study (interday & intraday) showed that the relative standard deviation is less than 2 %, show-ing method is well precise. Proposed validated HPTLC method is simple, precise, specific, robust and accu-rate, and could find application in routine quality-control analysis. The method was used for quantitative es-timation of gallic acid and quercetin in the polyherbal blend and was found as 1.648 % w/w and 3.165 % w/w respectively.